SalmeterolFluticasonpropionat

Hauptinformation

  • Handelsname:
  • Salmeterol/Fluticasonpropionat Easyhaler 50 Mikrogramm/500 Mikrogramm pro Inhalation, Pulver zur Inhalation
  • Darreichungsform:
  • Pulver zur Inhalation
  • Zusammensetzung:
  • Salmeterolxinafoat 73.µg; Fluticason-17-propionat 500.µg
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • für die Allgemeinheit:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie das Informationsblatt für die Öffentlichkeit.

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Salmeterol/Fluticasonpropionat Easyhaler 50 Mikrogramm/500 Mikrogramm pro Inhalation, Pulver zur Inhalation
    Deutschland
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte
  • Zulassungsnummer:
  • 99811.00.00
  • Letzte Änderung:
  • 04-05-2018

2-5-2018

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

17-5-2018

#ThrowBackThursday: May 17, 1971- The Public Health Service Bureau of Radiological Health transferred to FDA. It’s Mission: Protect against unnecessary human exposure to radiation from electronic products in the home and industry. #OnThisDay #FDAHistory

#ThrowBackThursday: May 17, 1971- The Public Health Service Bureau of Radiological Health transferred to FDA. It’s Mission: Protect against unnecessary human exposure to radiation from electronic products in the home and industry. #OnThisDay #FDAHistory

#ThrowBackThursday: May 17, 1971- The Public Health Service Bureau of Radiological Health transferred to FDA. It’s Mission: Protect against unnecessary human exposure to radiation from electronic products in the home and industry. #OnThisDay #FDAHistory

FDA - U.S. Food and Drug Administration

2-5-2018

FLUTICASONE PROPIONATE Spray, Metered [Rugby Laboratories]

FLUTICASONE PROPIONATE Spray, Metered [Rugby Laboratories]

Updated Date: May 2, 2018 EST

US - DailyMed

20-4-2018

ALLERGY RELIEF (Fluticasone Propionate) Spray, Metered [Topco Associates LLC]

ALLERGY RELIEF (Fluticasone Propionate) Spray, Metered [Topco Associates LLC]

Updated Date: Apr 20, 2018 EST

US - DailyMed

18-4-2018

Health Tip: Understanding Allergy Blood Testing

Health Tip: Understanding Allergy Blood Testing

Title: Health Tip: Understanding Allergy Blood TestingCategory: Health NewsCreated: 4/17/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

18-4-2018

Health Tip: If You're Pregnant and Have Diabetes

Health Tip: If You're Pregnant and Have Diabetes

Title: Health Tip: If You're Pregnant and Have DiabetesCategory: Health NewsCreated: 4/17/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

18-4-2018

Organs From Opioid OD Victims Are Saving Lives: Study

Organs From Opioid OD Victims Are Saving Lives: Study

Title: Organs From Opioid OD Victims Are Saving Lives: StudyCategory: Health NewsCreated: 4/17/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

18-4-2018

Go Nuts for Heart Health

Go Nuts for Heart Health

Title: Go Nuts for Heart HealthCategory: Health NewsCreated: 4/17/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

18-4-2018

Can Mom-to Be's' Weight Affect Daughters' Risk for Early Puberty?

Can Mom-to Be's' Weight Affect Daughters' Risk for Early Puberty?

Title: Can Mom-to Be's' Weight Affect Daughters' Risk for Early Puberty?Category: Health NewsCreated: 4/17/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

18-4-2018

'Flexitarian' Eating: Part Vegetarian, Part Not

'Flexitarian' Eating: Part Vegetarian, Part Not

Title: 'Flexitarian' Eating: Part Vegetarian, Part NotCategory: Health NewsCreated: 4/17/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

18-4-2018

Sen. John McCain Recovering After Intestinal Surgery

Sen. John McCain Recovering After Intestinal Surgery

Title: Sen. John McCain Recovering After Intestinal SurgeryCategory: Health NewsCreated: 4/17/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

18-4-2018

ALLERGY RELIEF (Fluticasone Propionate) Spray, Metered [Quality Home Products]

ALLERGY RELIEF (Fluticasone Propionate) Spray, Metered [Quality Home Products]

Updated Date: Apr 18, 2018 EST

US - DailyMed

17-4-2018

Autologous skeletal myoblasts expanded ex vivo (Assistance Publique - Hopitaux de Paris (APHP))

Autologous skeletal myoblasts expanded ex vivo (Assistance Publique - Hopitaux de Paris (APHP))

Autologous skeletal myoblasts expanded ex vivo (Active substance: Autologous skeletal myoblasts expanded ex vivo) - Refusal of orphan designation - Commission Decision (2018)2354 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/144/17

Europe -DG Health and Food Safety

3-4-2018

NASOPRO 24 (Fluticasone Propionate) Spray, Metered [H E B]

NASOPRO 24 (Fluticasone Propionate) Spray, Metered [H E B]

Updated Date: Apr 3, 2018 EST

US - DailyMed

1-4-2018

01.04.2018: Metoject 17.5 mg, Injektionslösung, Spritze(n), 39.35, -13.2%

ODDB.org: Open Drug DatabaseSwissmedic-Nummer57272090 ZulassungsinhaberGebro Pharma AGNameMetoject 17.5 mg, InjektionslösungRegistrierungsdatum02.09.2005Original/GenerikumOriginalErstzulassung Sequenz17.11.2011ATC-KlassierungMethotrexate (L04AX03)Revisionsdatum WHOWHO-DDDGültig bis01.09.2020Index Therapeuticus (BSV)07.10.60.PackungsgrösseSpritze(n)Index Therapeuticus (Swissmedic)07.10.60.Beschreibung AbgabekategorieA  SL EintragJaAnwendungArthritis und PsoriasisFachinformationFIP...

ODDB -Open Drug Database

28-3-2018

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Transfer of orphan designation - Commission Decision (2018)2011 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/17/T/01

Europe -DG Health and Food Safety

23-3-2018

Singulair vs. Flovent

Singulair vs. Flovent

Singulair (montelukast) and Flovent (fluticasone propionate) are used to treat or prevent asthma. Singulair is generally used to treat asthma and allergic rhinitis, and it is also used to prevent exercise-induced narrowing of the airways.

US - RxList

21-3-2018

EU/3/17/1861 (Roivant Sciences Ireland Limited)

EU/3/17/1861 (Roivant Sciences Ireland Limited)

EU/3/17/1861 (Active substance: (S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester) - Transfer of orphan designation - Commission Decision (2018)1826 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/299/16/T/01

Europe -DG Health and Food Safety

21-3-2018

Singulair vs. Advair

Singulair vs. Advair

Singulair (montelukast) and Advair HFA (salmeterol and fluticasone) are used to treat asthma. Singulair is also used to treat and allergic rhinitis and to prevent exercise-induced narrowing of the airways. Advair HFA is also used to treat chronic bronchitis.

US - RxList

13-3-2018

ADVAIR DISKUS (Fluticasone Propionate And Salmeterol) Powder [REMEDYREPACK INC.]

ADVAIR DISKUS (Fluticasone Propionate And Salmeterol) Powder [REMEDYREPACK INC.]

Updated Date: Mar 13, 2018 EST

US - DailyMed

12-3-2018

FLOVENT DISKUS (Fluticasone Propionate) Powder, Metered [Glaxo Operations UK Ltd]

FLOVENT DISKUS (Fluticasone Propionate) Powder, Metered [Glaxo Operations UK Ltd]

Updated Date: Mar 12, 2018 EST

US - DailyMed

12-3-2018

FLOVENT DISKUS (Fluticasone Propionate) Powder, Metered [Proficient Rx LP]

FLOVENT DISKUS (Fluticasone Propionate) Powder, Metered [Proficient Rx LP]

Updated Date: Mar 12, 2018 EST

US - DailyMed

1-3-2018

SIGNATURE CARE ALLERGY RELIEF (Fluticasone Propionate) Spray, Metered [Safeway]

SIGNATURE CARE ALLERGY RELIEF (Fluticasone Propionate) Spray, Metered [Safeway]

Updated Date: Mar 1, 2018 EST

US - DailyMed

1-3-2018

01.03.2018: Candesartan Takeda 8 mg, Tabletten, 28 Tablette(n), 17.90, -9.4%

ODDB.org: Open Drug DatabaseSwissmedic-Nummer62569004 CMZulassungsinhaberTakeda Pharma AGNameCandesartan Takeda 8 mg, TablettenRegistrierungsdatum12.03.2012Original/GenerikumOriginalErstzulassung Sequenz12.03.2012ATC-KlassierungCandesartan (C09CA06)Revisionsdatum WHOWHO-DDDGültig bis11.03.2022Index Therapeuticus (BSV)02.07.10.Packungsgrösse28 Tablette(n)Index Therapeuticus (Swissmedic)02.07.10.Beschreibung AbgabekategorieB  SL EintragJaAnwendungEssentielle Hypertonie und Herzinsu...

ODDB -Open Drug Database

26-2-2018

FLUTICASONE PROPIONATE Spray, Metered [Target Corporation]

FLUTICASONE PROPIONATE Spray, Metered [Target Corporation]

Updated Date: Feb 26, 2018 EST

US - DailyMed

22-2-2018

FLUTICASONE PROPIONATE Spray, Metered [Walmart]

FLUTICASONE PROPIONATE Spray, Metered [Walmart]

Updated Date: Feb 22, 2018 EST

US - DailyMed

21-2-2018

Airexar Spiromax (Teva B.V.)

Airexar Spiromax (Teva B.V.)

Airexar Spiromax (Active substance: salmeterol/fluticasone propionate) - Centralised - Yearly update - Commission Decision (2018)1122 of Wed, 21 Feb 2018

Europe -DG Health and Food Safety

21-2-2018

Aerivio Spiromax (Teva B.V.)

Aerivio Spiromax (Teva B.V.)

Aerivio Spiromax (Active substance: salmeterol/fluticasone propionate) - Centralised - Yearly update - Commission Decision (2018)1123 of Wed, 21 Feb 2018

Europe -DG Health and Food Safety

12-2-2018

Rheumatoid Arthritis (RA): 17 Warning Signs of Serious Complications

Rheumatoid Arthritis (RA): 17 Warning Signs of Serious Complications

Title: Rheumatoid Arthritis (RA): 17 Warning Signs of Serious ComplicationsCategory: Doctor's & Expert's views on SymptomsCreated: 7/7/2001 12:00:00 AMLast Editorial Review: 2/12/2018 12:00:00 AM

US - MedicineNet

1-2-2018

01.02.2018: Actemra 80 mg/4 ml, Konzentrat zur Herstellung einer Infusionslösung, Durchstechflasche(n), 209.25, -10.9%

ODDB.org: Open Drug DatabaseSwissmedic-Nummer58868001 ZulassungsinhaberRoche Pharma (Schweiz) AGNameActemra 80 mg/4 ml, Konzentrat zur Herstellung einer InfusionslösungRegistrierungsdatum02.12.2008  Erstzulassung Sequenz02.12.2008ATC-KlassierungTocilizumab (L04AC07)Revisionsdatum WHOWHO-DDDGültig bis01.12.2018Index Therapeuticus (BSV)07.15.PackungsgrösseDurchstechflasche(n)Index Therapeuticus (Swissmedic)07.15.Beschreibung AbgabekategorieA  SL EintragJaAnwendungRheumato...

ODDB -Open Drug Database

1-2-2018

01.02.2018: Actemra 200 mg/10 ml, Konzentrat zur Herstellung einer Infusionslösung, Durchstechflasche(n), 498.45, -11.4%

ODDB.org: Open Drug DatabaseSwissmedic-Nummer58868002 ZulassungsinhaberRoche Pharma (Schweiz) AGNameActemra 200 mg/10 ml, Konzentrat zur Herstellung einer InfusionslösungRegistrierungsdatum02.12.2008  Erstzulassung Sequenz02.12.2008ATC-KlassierungTocilizumab (L04AC07)Revisionsdatum WHOWHO-DDDGültig bis01.12.2018Index Therapeuticus (BSV)07.15.PackungsgrösseDurchstechflasche(n)Index Therapeuticus (Swissmedic)07.15.Beschreibung AbgabekategorieA  SL EintragJaAnwendungRheuma...

ODDB -Open Drug Database

1-2-2018

01.02.2018: Actemra 400 mg/20 ml, Konzentrat zur Herstellung einer Infusionslösung, Durchstechflasche(n), 980.55, -11.3%

ODDB.org: Open Drug DatabaseSwissmedic-Nummer58868003 ZulassungsinhaberRoche Pharma (Schweiz) AGNameActemra 400 mg/20 ml, Konzentrat zur Herstellung einer InfusionslösungRegistrierungsdatum02.12.2008  Erstzulassung Sequenz02.12.2008ATC-KlassierungTocilizumab (L04AC07)Revisionsdatum WHOWHO-DDDGültig bis01.12.2018Index Therapeuticus (BSV)07.15.PackungsgrösseDurchstechflasche(n)Index Therapeuticus (Swissmedic)07.15.Beschreibung AbgabekategorieA  SL EintragJaAnwendungRheuma...

ODDB -Open Drug Database

30-1-2018

FLUTICASONE PROPIONATE Cream [Proficient Rx LP]

FLUTICASONE PROPIONATE Cream [Proficient Rx LP]

Updated Date: Jan 30, 2018 EST

US - DailyMed

24-1-2018

EU/3/17/1971 (Edison Orphan Pharma BV)

EU/3/17/1971 (Edison Orphan Pharma BV)

EU/3/17/1971 (Active substance: Vatiquinone) - Orphan designation - Commission Decision (2018)393 of Wed, 24 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/145/17

Europe -DG Health and Food Safety

22-1-2018

ALLERGY NASAL (Fluticasone Propionate) Spray, Metered [Walgreen Company]

ALLERGY NASAL (Fluticasone Propionate) Spray, Metered [Walgreen Company]

Updated Date: Jan 22, 2018 EST

US - DailyMed

20-1-2018

EU/3/17/1965 (Duchenne UK)

EU/3/17/1965 (Duchenne UK)

EU/3/17/1965 (Active substance: Metformin and L-citrulline) - Orphan designation - Commission Decision (2018)387 of Sat, 20 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/154/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1958 (Voisin Consulting S.A.R.L.)

EU/3/17/1958 (Voisin Consulting S.A.R.L.)

EU/3/17/1958 (Active substance: Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1) - Orphan designation - Commission Decision (2018)379 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/192/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1970 (Rare Partners srl Impresa Sociale)

EU/3/17/1970 (Rare Partners srl Impresa Sociale)

EU/3/17/1970 (Active substance: Sirolimus) - Orphan designation - Commission Decision (2018)392 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1967 (Millendo Therapeutics Ltd)

EU/3/17/1967 (Millendo Therapeutics Ltd)

EU/3/17/1967 (Active substance: N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt) - Orphan designation - Commission Decision (2018)389 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/179/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1957 (uniQure Biopharma B.V.)

EU/3/17/1957 (uniQure Biopharma B.V.)

EU/3/17/1957 (Active substance: Adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene) - Orphan designation - Commission Decision (2018)378 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/151/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1956 (Quintiles Ireland Limited)

EU/3/17/1956 (Quintiles Ireland Limited)

EU/3/17/1956 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene) - Orphan designation - Commission Decision (2018)377 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/168/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1955 (Quintiles Ireland Limited)

EU/3/17/1955 (Quintiles Ireland Limited)

EU/3/17/1955 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene) - Orphan designation - Commission Decision (2018)376 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/167/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1966 (Sirius Regulatory Consulting Limited)

EU/3/17/1966 (Sirius Regulatory Consulting Limited)

EU/3/17/1966 (Active substance: N-(bromoacetyl)-3,3-dinitroazetidine) - Orphan designation - Commission Decision (2018)388 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/166/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1964 (Incyte Biosciences UK Ltd)

EU/3/17/1964 (Incyte Biosciences UK Ltd)

EU/3/17/1964 (Active substance: Itacitinib) - Orphan designation - Commission Decision (2018)385 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/169/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1963 (Professor Pascale De Lonlay)

EU/3/17/1963 (Professor Pascale De Lonlay)

EU/3/17/1963 (Active substance: Hydroxychloroquine sulphate) - Orphan designation - Commission Decision (2018)384 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/177/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1962 (MWB Consulting Ltd)

EU/3/17/1962 (MWB Consulting Ltd)

EU/3/17/1962 (Active substance: Humanised Fc-engineered monoclonal antibody against CD19) - Orphan designation - Commission Decision (2018)383 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/155/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1961 (Astellas Pharma Europe B.V.)

EU/3/17/1961 (Astellas Pharma Europe B.V.)

EU/3/17/1961 (Active substance: Gilteritinib) - Orphan designation - Commission Decision (2018)382 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/175/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1960 (Atlas Molecular Pharma S.L.)

EU/3/17/1960 (Atlas Molecular Pharma S.L.)

EU/3/17/1960 (Active substance: Ciclopirox) - Orphan designation - Commission Decision (2018)381 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/186/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1959 (GW Research Ltd)

EU/3/17/1959 (GW Research Ltd)

EU/3/17/1959 (Active substance: Cannabidiol) - Orphan designation - Commission Decision (2018)380 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/165/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1969 (University of Cambridge)

EU/3/17/1969 (University of Cambridge)

EU/3/17/1969 (Active substance: Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits) - Orphan designation - Commission Decision (2018)391 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/182/17

Europe -DG Health and Food Safety

19-1-2018

EU/3/17/1968 (Regintel Limited)

EU/3/17/1968 (Regintel Limited)

EU/3/17/1968 (Active substance: Pyrazolo[1,5-a]pyrimidine, 3-[4-chloro-2-(4-morpholinyl)-5-thiazolyl]-7-(1-ethylpropyl)-2,5-dimethyl-pyrazolo[1,3-a]pyrimidine) - Orphan designation - Commission Decision (2018)390 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/164/17

Europe -DG Health and Food Safety